首页>投融资
Kiora Pharmaceuticals
上市后再融资
Kiora Pharmaceuticals, Inc.于2004年12月26日以EyeGate Pharmaceuticals, Inc.的名义成立为特拉华州公司,并于2021年11月8日起更名为Kiora Pharmaceuticals, Inc.。该公司是一家临床阶段的专业制药公司专注于开发和商业化用于治疗眼疾的疗法和药物输送。
基本信息
-
公司全称Kiora Pharmaceuticals Inc
-
类型药物研发制造商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数15人以下
-
地址332 Encinitas Blvd. Suite 102 Encinitas CA 92024
-
联系电话1-781-7888869
-
邮箱sdfrom@eyegatepharma.com
-
成立时间1998-01-01
投融资
-
2023-06-06上市后再融资630万美元未透露
-
2022-11-18上市后再融资312万美元未透露
-
2022-07-26上市后再融资600万美元未透露
-
2021-08-10上市后再融资1075万美元未透露
-
2021-01-06上市后再融资800万美元Armistice Capital
-
2019-12-17上市后再融资190万美元未透露
-
2015-08-07上市未透露未透露
-
2015-07-31上市924.9995万美元未透露
-
2011-01-07D轮590万美元未透露
-
2010-01-08D轮2260万美元Natixis Private EquityVentechInnoven PartnersMedicis CapitalGeneris Capital Partners
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国):Veradermics是一家位于美国的生物技术公司,专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台,开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,